Dishman Carbogen Amcis Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9w13amh6m1yjtyyg0gb3qwhh.pdf

Key Takeaways


The Geopolitical Cost Shock

Dalal: "While we do expect that most of this cost would be passed on to the customers in the foreseeable future, there is definitely a time lag due to the already accepted orders, as well as the competition."

Carbogen Amcis: The Development Backlog Is the Story

Villemagne: "We actually do sometimes more money into the development phase because there is a lot to do than a commercial side. In the commercial side, then we start to have a big pressure on pricing. ... So, we do more margins on the R&D phase."

BV Business: A Perfect Storm, Not a Structural Break

Villemagne: "I fully understand the disappointment and we are the first to be disappointed in that matter. We really are looking to get back on track earlier, but of course the significant events and situation in Ukraine has affected a lot of the raw materials for instance on the cost of energy which affected our revenues."

French Fill-and-Finish Facility: The Next Growth Leg

Villemagne: "We successfully conclude some great negotiations from the petroleum point of view and we kept our customer control over the construction of that inside, which is going to give us a significant competitive advantage in front of some competitors that are building the same kind of facility."

India Business & Regulatory Recovery


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthAt least 10%, higher side 12–14%FY23 full year
EBITDA marginAround 20% for the full yearFY23 full year
Dutch business margin recoveryMargins to reach 25–30%Remaining three quarters of FY23
Cost pass-through visibilityFull effect of pass-through to customers visibleAt least two quarters
French facility openingFacility opens, new revenue stream beginsQ1 FY24
French facility first projectFirst project launch from new facilityEnd of Q1 CY23
Bavla EDQM reinspection readinessReady to inform authority for reinspectionOctober 2022
India business normalcy70% normalcy achievedFY23
Molecule commercialization3 projects very likely to come to marketNext 12–15 months
No major FX loan loss repeatNo large bullet repayments dueNext nine months

Key Metrics

MetricQ1 FY23
Consolidated revenue from operations₹541 cr
Gross contribution~82%, management aims for ~20% cost
Reported EBITDA₹88 cr
Normalized EBITDA~₹90 cr, adjusting for ~₹2 cr FX interpretation impact
Employee expenses₹256 cr, in line with Q4 FY22, expected to remain in this range for remainder FY23
Other expenses₹104 cr, includes FX loss of ~₹9 cr
Finance cost₹19 cr, includes FOREX loss of ₹3 cr
Dishman India APIs and intermediates revenue₹62 cr, ~92% YoY growth from ₹32 cr in Q1 FY22
Focus generics revenue₹51 cr, 7% growth
Carbogen Amcis CRAMS revenue₹363 cr, ~3% YoY growth
Carbogen Amcis BV (cholesterol and Vitamin D analogs) revenue₹63 cr, 46% YoY drop; last year Q1 had a single customer supply comprising ~38% of annual revenue
India APIs and intermediates EBITDA margin~10%
Carbogen Amcis CRAMS EBITDA margin19.4%
Cholesterol and Vitamin D analog business EBITDA margin19.3%, historically ~30%; drop due to higher wool grease prices and energy costs
Development orders yet to start$96 million, providing visibility for next 12 months
Phase-III molecules in CRAMS portfolio17 molecules
Molecules moved from development to commercialization in last three years6 to 7 molecules
Molecules very likely to come to market in next 12 to 15 months3 projects
Total molecules across different phases of development~450 molecules
FY23 revenue growth guidanceAt least 10%, on the higher side 12% to 14%
FY23 EBITDA margin guidanceAround 20% for the full year
FX exposures hedged for remainder of FY2360% to 70%
Energy cost differential in Netherlands vs Q1 FY22~3x to 3.5x